KRAS and non-small cell lung carcinoma: Patients with a PD-L1 expression more than or equal to 50% who received combination chemoimmunotherapy had a median OS of 13.2 months (95% CI: 6.9–not evaluable) for those with KRAS G12C-mutated NSCLC and 30.5 months (95% CI:14.0–not evaluable) for those with KRAS non–G12C-mutated NSCLC (Fig. 3).